ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Advanced Therapeutic Approach Based on LDHs-Mimetic Oxidoreductase.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Redox-immune modulating gadolinium vanadate based nanozymes for osteoarthritis therapy.Materials today. Bio · 2026Article
- Synergistic disruption of redox and energy homeostasis via high-entropy layered double hydroxide nanozymes for enhanced tumor therapy.iScience · 2026Article
- Recent advances in engineered nanozymes for precision lung cancer therapy.Materials today. Bio · 2026Review
- High-entropy layered double hydroxide nanosheets reprogram tumor homeostasis for ultrasound-enhanced pyroptosis-mediated immunotherapy.Journal of nanobiotechnology · 2026Article
- Advanced Therapeutic Approach Based on LDHs-Mimetic Oxidoreductase.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Redox dysregulation is recognized as a key driver in the pathophysiology of numerous refractory diseases, contributing significantly to the progression and poor prognosis. The precise targeting and sophisticated modulation of redox processes within pathological microenvironments thus offer a promising avenue for innovative therapeutic strategies. Layered double hydroxides (LDHs)-based nanozyme lies in the programmable multi-active site architecture, which enables unprecedented functional integration for precise pathological microenvironment remodeling. In this review, the redox modulating mechanisms of LDHs-based nanozyme in these critical disease contexts are systematically explored, with special emphasis on intrinsic enzyme-like activities and structure-activity relationships. At the same time, it highlights how designing LDHs-based nanozyme can manipulate redox homeostasis to precisely reprogram the pathological microenvironment for stimulating effective, context-dependent pro- and anti-inflammatory therapeutic outcomes, which is a crucial requirement in conditions such as tumors and tissue injury. Finally, building upon recent advances, a forward-looking perspective is provided on the current challenges and future research directions in this rapidly progressing field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.